Ph.D. Niro Ramachandran - 13 Apr 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Business Officer
Signature
/s/ Niro Ramachandran, Ph.D., by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
13 Apr 2022
Net transactions value
+$68,347
Form type
4
Filing time
14 Apr 2022, 15:23:26 UTC
Previous filing
25 Mar 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $68,347 +75,107 +158% $0.9100* 122,680 13 Apr 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -75,107 -44% $0.000000 96,566 13 Apr 2022 Common Stock 75,107 $0.9100 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as follows: one-fourth (1/4) of the shares on July 13, 2021 and the remaining shares shall vest in 36 equal monthly installments beginning on July 13, 2021, until fully vested, subject to reporting person's continuous employment